byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmológicos - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmológicos - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmológicos - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
lucentis
novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - oftalmológicos - lucentis é indicado em adultos para o tratamento de neovascular (úmida) degeneração macular relacionada à idade (amd)o tratamento da deficiência visual, devido a choroidal neovascularisation (cnv)o tratamento da deficiência visual, devido ao diabético macular, edema (dme)o tratamento da deficiência visual, devido à macular, edema secundário à oclusão da veia da retina (ramo rvo ou central rvo).
lucentis
novartis biociencias s.a - ranibizumabe - outros medicamentos com acao no aparelho visual
amelivu
samsung bioepis br pharmaceutical ltda. - ranibizumabe - outros medicamentos com acao no aparelho visual
eylea
bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - oftalmológicos - eylea é indicado para adultos para o tratamento de:neovascular (úmida) degeneração macular relacionada à idade (amd);deficiência visual devido à macular, edema secundário à oclusão da veia da retina (ramo rvo ou central rvo);deficiência visual devido ao diabético macular, edema (dme);deficiência visual devido a míopes choroidal neovascularisation (míope cnv).
yesafili
viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - oftalmológicos - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.
eylia
bayer s.a. - aflibercepte - outros medicamentos com acao no aparelho visual
ipique
rotterdam biologics b.v. - bevacizumab - degeneração macular úmida - oftalmológicos - treatment of neovascular (wet) age-related macular degeneration (amd).